Summary

Other Scenarios:

Buyer: Forest Laboratories, Inc. (FRX) Last Price: 39.18 Market Cap.: 12.77B
Target: Neurocrine Biosciences, Inc. (NBIX) Last Price: 52.74 Market Cap.: 1.99B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 861
Biopharmaceuticals 315
Cardiovascular System 18
Digestive System   5
Endocrinology/Metabolism 10
Immunology 10
Infectious Diseases   31
Musculoskeletal System   3
Neurology 31
Obstetrics/Gynecology 3
Oncology   73
Pain Management 5
Respiratory System   6
Toxicology   0
Urology   4
Weight Management   1
Medical Devices   247
Drug Delivery   14

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 29)
  • Namenda (Memantine)
  • Neramexane
  • RGH-188 (Dopamine Receptor Agonist)
  • Lexapro (Escitalopram Oxalate)
Target (Total: 21)
  • NBI-75043
  • NBI-34041 (CRF R1 Antagonist)
  • NBI-5788 (Altered Peptide Ligand)
  • CRF R1 Antagonist
Buyer
  • Tiazac (Diltiazem)
  • Bertek Nebivolol
  • Desmoteplase
  • Benicar (Olmesartan Medoxomil)
Target
  • Urocortin 2
  • CRF R1 Antagonist
  • NBI-6024 (Altered Peptide Ligand)
  • NBI-5788 (Altered Peptide Ligand)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 6)
  • Biovail Corporation (USA) (BVF)
  • Mack-Cali Realty Corp. (CLI)
  • Dendrite International, Inc. (DRTE)
  • Phase Forward Incorporated (PFWD)
Target (Total: 2)
  • Pfizer Inc. (PFE)
  • Open Text Corporation (USA) (OTEX)
Buyer (Total: 4)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Cardinal Health, Inc. (CAH)
  • Neurobiological Tech. (NTII)
Target (Total: 5)
  • Pfizer Inc. (PFE)
  • GlaxoSmithKline plc (ADR) (GSK)
  • Wyeth (WYE)
  • Eli Lilly & Co. (LLY)

Key Financial Summary:

Metric Buyer Target
Number of Employees 5,136 564
Revenue Per Employee 591,371.2 139,496.5
Total Revenue 756.3 19.5
Total Expenses 621.3 47.1
Other Revenue 12.3 8.2
Cost of Revenue 167.9 0.0
SG&A Expense 259.0 19.3
Research & Development 194.4 27.7
Other Operating Expense 0.0 0.0
Operating Income 135.1 -27.6
Unusual Income 0.0 0.0
Gross Margin % 77.81 100
Metric Buyer Target
Operating Margin % 17.86 -141.68
Total Assets n/a 477.4
Return on Equity % n/a -27.6
Cash+ ST Inv. Per Share n/a 7.08
Total Debt 0.0 57.9
Curr Portion of LTD/Cap Lease n/a 5.5
Total Debt to Equity n/a 15.1
LT Debt to Capital n/a 12.01
Fwd P/E 16.73 76.40
Fwd P/Rev 4.03 9.57
Book Value n/a 383.8

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Neurology

Target

Focused (): *Healthcare > Biopharmaceuticals > Neurology

Business Description

Buyer

Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over the counter (OTC). The Company's products in United States consist of branded ethical drug specialties marketed directly or detailed to physicians by the Company's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales forces. The Company's products include Lexapro, Celexa, Namenda, Benicar, Campral, Combunox, RGH-188, GRC 3886, Desmoteplase, CCR1 Antagonists, Milnacipran, Tiazac and Lercanidipine.

Target

Neurocrine Biosciences, Inc. discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company's product candidates address pharmaceutical markets in the world, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company has nine programs in various stages of research and development, including seven programs in clinical development. While the Company independently develops many of its product candidates, it has entered into collaborations for three of its programs. The Company's lead clinical development program, indiplon, is a drug for the treatment of insomnia. It has submitted two New Drug Applications (NDAs) to the United States Food and Drug Administration (FDA) with respect to indiplon.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Tiazac (Diltiazem)
  
Heart Failure (HF)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Bertek Nebivolol
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Desmoteplase

Target Products:

  • Urocortin 2
Vascular Disorders  
Hypertension  
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.

Buyer Products:

  • Benicar (Olmesartan Medoxomil)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Benicar HCT (Olmesartan Medoxomil/Hydrochlorothiazide)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Bertek Nebivolol
  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Tiazac (Diltiazem)
  
Digestive System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Target Products:

  • CRF R1 Antagonist
  
Endocrinology/Metabolism
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • NBI-6024 (Altered Peptide Ligand)
  
Thyroid Gland Disorders  
Hypothyroidism  
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.

Buyer Products:

  • Armour Thyroid (Thyroid Tablets)
  • Thyrolar (Liotrix)
  • Levothroid (Levothyroxin Sodium)
  
Immunology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Target Products:

  • NBI-5788 (Altered Peptide Ligand)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • CCR1 (Chemokine Receptor) Program

Target Products:

  • CCR7
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Carbapenems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Faropenem Medoxomil
  
Viral  
RNA Viruses  
Orthomyxovirus  
Influenza A  
Viral Uncoating Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the removal of the protective shield around the viral genome, thus preventing the release of viral DNA into the host.

Buyer Products:

  • Flumadine (Rimantadine Hydrochloride)
  
Musculoskeletal System  
Skeletal Disorders  
Joint Disorders  
Fibromyalgia Syndrome (FMS)  
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat Fibromyalgia Syndrome by preventing reuptake of serotonin and norepinephrine.

Buyer Products:

  • Milnacipran
  
Neurology
Neurological Disorders  
Alzheimer`s Disease  
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
Therapeutics that treat the disorders involving the progressive degeneration and death of brain cells by preventing the actions of an amino acid neurotransmitter, N-Methyl-D-Aspartate.

Buyer Products:

  • Namenda (Memantine)
  • Neramexane
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • RGH-188 (Dopamine Receptor Agonist)
  • Namenda (Memantine)

Target Products:

  • NBI-75043
  • NBI-34041 (CRF R1 Antagonist)
  • NBI-5788 (Altered Peptide Ligand)
  • CRF R1 Antagonist
Psychiatric Disorders
Anxiety  
Generalized Anxiety Disorder (GAD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.

Buyer Products:

  • Lexapro (Escitalopram Oxalate)
  
Panic Disorder  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Lexapro (Escitalopram Oxalate)
  
Social Anxiety Disorder (SAD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Lexapro (Escitalopram Oxalate)
  
Mood Disorders  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Buyer Products:

  • Celexa (Citalopram Hydrobromide)
  • Lexapro (Escitalopram Oxalate)
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Target Products:

  • Indiplon Immediate Release Capsule
  • Indiplon Modified Release Tablet
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • mGLUR1/5 Compounds

Target Products:

  • Adenosine 2A Receptor Antagonists
  • Sleep Program
  • Excitatory Amino Acid Transporters
  • CRF R2 Antagonist
  • MC-4 (Melanin Concentrating Hormone Antagonist)
  • Melanocortin Receptor Agonist
Obstetrics/Gynecology
Child Birth/Pregnancy  
Induction/Cervical Ripening  
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.

Buyer Products:

  • Cervidil Vaginal Insert (Dinoprostone)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Target Products:

  • D2 Receptor Agonist
  • NBI-56418 (GnRH Antagonist)
  • NBI-42902 (GnRH Antagonist)
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • NBI-42902 (GnRH Antagonist)
  • NBI-3001 (IL-4 Fusion Toxin)
  
Pain Management
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Combunox (Oxycodone/Ibuprofen)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • Namenda (Memantine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Target Products:

  • Fractalkine
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Buyer Products:

  • Aerospan (Flunisolide Hydrofluoroalkane)
  • Aerobid (Flunisolide)
  
Chronic Obstructive Pulmonary Disease (COPD)  
Prophylactic Treatments  
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.

Buyer Products:

  • LAS34273
  
Respiratory Distress Syndrome (RDS)  
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.

Buyer Products:

  • Infasurf (Calfactant)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • RGH-896 (Selective NR2B Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • GRC 3886
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antitussives
Therapeutics that relieve or prevent coughs.

Buyer Products:

  • Tessalon (Benzonatate)
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Buyer Products:

  • Campral (Acamprosate)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • D2 Receptor Agonist
  • NBI-56418 (GnRH Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.

Target Products:

  • MC-4 (Melanin Concentrating Hormone Antagonist)
  
Weight Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Target Products:

  • MC-4 (Melanin Concentrating Hormone Antagonist)
  • Melanocortin Receptor Antagonist
  • Melanocortin Receptor Agonist
  
Medical Devices  
Drug Delivery  
Pulmonary Delivery  
Aerosol Therapy  
Vapor Therapy  
Accessories
Auxiliary medical devices designed to assist in the pulmonary delivery of metered dose of medication

Buyer Products:

  • AeroChamber Series
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,262.693 n/a 19.68 4.32 2.88 -38.67
King Pharmaceuticals n/a 4,396.073 44.83 12.63 2.33 2.45 4.68
Vanda Pharmaceuticals Inc. n/a 224.011 n/a n/a n/a n/a 10.43
Buyer
  GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,262.693 n/a 19.68 4.32 2.88 -38.67
Target
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Roche Holding Ltd. (ADR) n/a 139,217.584 30.89 23.81 5.03 4.59 7.93
sanofi-aventis (ADR) n/a 133,880.824 47.13 13.63 3.72 3.79 n/a
Merck & Co., Inc. n/a 74,838.163 15.73 14.38 3.39 3.62 4.33
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Abbott Laboratories n/a 63,215.948 18.80 16.88 2.86 2.88 13.96
Eli Lilly & Co. n/a 57,003.803 27.53 16.28 3.84 3.73 4.87
Bristol Myers Squibb Co. n/a 47,761.793 14.99 20.69 2.47 2.53 10.22
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,262.693 n/a 19.68 4.32 2.88 -38.67
Schering AG (ADR) n/a 20,873.552 25.05 25.69 2.96 n/a 5.77
Biogen Idec Inc n/a 15,803.911 65.79 23.81 6.46 6.14 5.09
Forest Laboratories, Inc. n/a 12,768.375 18.73 16.73 4.31 4.03 n/a
Serono S.A. (ADR) n/a 10,241.916 15.98 15.03 3.86 3.69 4.86
Elan Corporation, plc (ADR) n/a 6,801.639 n/a -18.73 13.03 10.07 -10.61
King Pharmaceuticals n/a 4,396.073 44.83 12.63 2.33 2.45 4.68
Arena Pharmaceuticals, Inc. n/a 630.127 n/a -6.94 27.12 16.57 4.46
Somaxon Pharmaceuticals, Inc. n/a 344.847 n/a -7.54 n/a 3.12 3.69
Vanda Pharmaceuticals Inc. n/a 224.011 n/a n/a n/a n/a 10.43

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Biovail Corporation (USA) n/a 4,342.384 18.34 12.44 4.64 4.37 20.70
Mack-Cali Realty Corp. n/a 2,760.618 21.57 12.31 4.22 4.27 1.83
Dendrite International, Inc. n/a 513.685 21.66 48.36 1.17 1.20 3.64
Phase Forward Incorporated n/a 401.040 99.64 42.59 4.45 3.81 9.47
PHC, Inc. n/a 38.180 13.79 n/a 1.07 n/a 7.50
H. Lundbeck A/S n/a n/a n/a n/a n/a n/a n/a
Target
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
Open Text Corporation (USA) n/a 713.679 393.02 15.40 1.73 1.75 8.73

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  McKesson Corporation 33.00% 14,632.871 19.31 18.30 0.17 0.16 3.73
AmerisourceBergen Corp. 28.00% 9,231.394 27.03 21.13 0.16 0.16 4.86
Cardinal Health, Inc. 25.00% 27,758.866 29.94 21.57 0.35 0.35 7.37
Neurobiological Tech. n/a 93.999 n/a -5.71 17.74 16.54 -26.57
Target
  Pfizer Inc. 90.80% 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) 9.20% 165,878.661 17.69 17.38 3.93 3.96 18.50
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Eli Lilly & Co. n/a 57,003.803 27.53 16.28 3.84 3.73 4.87
Taisho Pharmaceuticals Co. Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Almirall Prodesfarma, S.A. n/a n/a n/a n/a n/a n/a n/a
Buyer
  Mylan Laboratories Inc. n/a 4,388.706 26.46 17.96 3.49 3.42 5.57
Biovail Corporation (USA) n/a 4,342.384 18.34 12.44 4.64 4.37 20.70
Cypress Bioscience, Inc. n/a 239.281 n/a -16.70 28.53 42.84 2.66
Neurobiological Tech. n/a 93.999 n/a -5.71 17.74 16.54 -26.57
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
H. Lundbeck A/S n/a n/a n/a n/a n/a n/a n/a
Recordati S.A. Chemical and Pharmaceutical Company n/a n/a n/a n/a n/a n/a n/a
Target
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Eli Lilly & Co. n/a 57,003.803 27.53 16.28 3.84 3.73 4.87
Biosite Incorporated n/a 819.734 15.51 20.96 2.78 2.61 2.67
DOV Pharmaceutical, Inc. n/a 165.879 n/a -2.70 19.18 10.02 -8.59
Pharmacopeia Drug Discovery, Inc. n/a 78.860 n/a -7.47 3.87 3.76 2.24
Deltagen, Inc. n/a 23.311 n/a n/a 3.48 n/a 2.40
Taisho Pharmaceuticals Co. Ltd. n/a n/a n/a n/a n/a n/a n/a
Almirall Prodesfarma, S.A. n/a n/a n/a n/a n/a n/a n/a
Oregon Health Sciences University n/a n/a n/a n/a n/a n/a n/a
Memorial Sloan-Kettering Cancer Center n/a n/a n/a n/a n/a n/a n/a
University Of Michigan n/a n/a n/a n/a n/a n/a n/a
Wisconsin Alumni Research Foundation n/a n/a n/a n/a n/a n/a n/a
The Salk Institute for Biological Studies n/a n/a n/a n/a n/a n/a n/a
Mount Sinai Medical Center n/a n/a n/a n/a n/a n/a n/a
University of Virginia n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 2,912.1 102.3 3,014.4
Other Revenue 50.3 29.2 79.5
Total Revenue 2,962.4 131.5 3,093.9
Cost of Revenue 651.0 0.0 651.0
SG&A Expense 1,031.5 56.1 1,087.5
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 410.4 108.8 519.2
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 2,092.9 164.8 2,257.7
Operating Income 869.5 -33.3 836.2
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 0.0 4.1 4.1
Other, Net 0.0 0.0 0.0
Income Before Taxes 869.5 -29.3 840.2
Income Taxes 161.0 0.0 161.0
Income After Taxes 708.5 -29.3 679.3
Net Income - Excl. Xord. Items 708.5 -29.3 679.3
Net Income - Incl. Xord. Items 708.5 -29.3 679.3
Income Avail. to Common 708.5 -29.3 679.3
Share Items
Basic Avg. Shares Outstanding 325.5 37.4 362.8
Basic EPS - Excl. Xord. Items 2.09 -0.78 1.87
Basic EPS - Incl. Xord. Items 2.09 -0.78 1.87
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 330.0 37.4 367.3
F.D. EPS - Excl. Xord. Items 2.07 -0.81 1.85
F.D. EPS - Incl. Xord. Items 2.07 -0.81 1.85
Balance Sheet
Assets
Cash and Equivalents n/a 101.5 101.5
ST Investments n/a 163.0 163.0
Accounts Receivable n/a 5.9 5.9
Inventory n/a 0.0 0.0
Other Current Assets n/a 4.3 4.3
Current Assets n/a 274.7 274.7
Accum D&A n/a 0.0 0.0
PPE, Net n/a 97.4 97.4
Goodwill & Intangibles n/a 0.0 0.0
Other Assets n/a 0.0 0.0
Other LT Assets n/a 105.3 105.3
Total Assets n/a 477.4 477.4
Liabilities
Accounts Payable n/a 0.0 0.0
Payable/Accrued n/a 16.8 16.8
ST Debt n/a 0.0 0.0
Curr Port of LTD & Cap Lease Oblg n/a 5.5 5.5
Other (Current) Liabilities n/a 10.4 10.4
Current Liab. n/a 32.8 32.8
LT Debt n/a 0.0 0.0
Capitalized Lease Obligations n/a 52.4 52.4
Total LT Debt n/a 52.4 52.4
Other LT Liab. n/a 8.4 8.4
Total Liabilities n/a 93.6 93.6
Shareholders Equity
Common Stock n/a 0.0 0.0
Additional Paid in Capital n/a 711.0 711.0
Retained Earnings n/a -326.0 -326.0
Other Equity n/a -1.2 -1.2
Total Equity n/a 383.8 383.8
Total Liab. & Equity n/a 477.4 477.4
Shares Outstanding n/a 37.7 37.7
Cash Flow
Operating Cash Flow
CF Net Income n/a -29.3 -29.3
CF Depreciation n/a 10.3 10.3
CF Deferred Taxes n/a 0.0 0.0
Other Non-Cash Items n/a -14.1 -14.1
Change in Working Capital n/a 7.9 7.9
Total Cash From Operating Activities n/a -25.2 -25.2
Investing Cash Flow
Capital Expenditures n/a -6.4 -6.4
Other Investing Cash Flows n/a 64.8 64.8
Total Cash From Investing Activities n/a 58.4 58.4
Financing Cash Flow
Dividends Paid n/a 0.0 0.0
Purchase Or Sale of Stock n/a 30.1 30.1
Purchase and Retirement of Debt n/a -6.5 -6.5
Other Financing Cash Flow n/a 0.1 0.1
Total Cash From Financing Activities n/a 23.7 23.7
Exchange Rate Effects n/a 0.0 0.0
Net Change in Cash n/a 56.9 56.9
Cash Interest Paid n/a 4.5 4.5